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Abstract
Consistent evidence links major depression and its affective components to negative health outcomes. Although
the pathways of these effects are likely complex and multifactorial, recent evidence suggests that innate
inflammatory processes may play a role. An overview of current literature suggests that pathways between
negative moods and inflammation are bi-directional. Indeed, negative moods activate peripheral physiologic
mechanisms that result in an up regulation of systemic levels of inflammation. Conversely, peripheral inflammatory
mediators signal the brain to affect behavioral, affective and cognitive changes that are consistent with symptoms
of major depressive disorder. It is likely that these pathways are part of a complex feedback loop that involves the
nervous, endocrine, and immune systems and plays a role in the modulation of peripheral inflammatory responses
to central and peripheral stimuli, in central responses to peripheral immune activation and in the maintenance of
homeostatic balance. Further research is warranted to fully understand the role of central processes in this
feedback loop, which likely contributes to the pathophysiology of mental and physical health.
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Background
Evidence shows an association of major depression with
increased risk for adverse physical health outcomes.
Indeed, depression, whether assessed as a continuum of
symptoms or as the presence of a clinical syndrome,
predicts the incidence and progression of diseases of
aging, including cardiovascular, metabolic and neurode-
generative diseases, as well as all-cause mortality [1-3].
Given the burden of these physical illnesses, it is not
surprising that affective symptoms and disorders are
more prevalent among the medically-ill than the general
population [4,5], raising the possibility that associations
between affective disorders and physical health are bi-
directional in nature. It is also likely that lifestyle
choices contribute to poorer health among individuals
with depression [6]; however, to date, evidence suggests
that behavioral factors contribute only minimally to
depression-related variability in health risk. Thus, other
mechanisms must also be operating. Accumulating evi-
dence suggests that the immune system may play a role.
Main Text
Early studies show an association of depression with the
down-regulation of functional parameters of the
immune system (for example, decreased ability of NK
cells to destroy tumor cells [7]). However, this immune
suppression is not as ‘global’ as initially proposed.
Indeed, recent attention has focused on the activation of
innate, non-specific inflammatory mechanisms that also
accompany depressed mood [8]. These differential
immune responses to negative mood have been inter-
preted within an evolutionary context as a down-regula-
tion of processes that take time and energy in favor of
an up-regulation of processes that are immediately avail-
able to defend the organism [9]. Although adaptive and
of potential health benefit in the short-term, growing
evidence shows that chronic elevation of inflammation
plays a role in the pathogenesis and course of numerous
age-related physical health conditions, possibly* Correspondence: marsland@pitt.edu
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contributing to the co-morbidity of depression with
chronic physical illness [10].
The inflammatory response is a non-specific immune
reaction that is initiated when monocytes/macrophages
are activated by pathogens or tissue damage to release
pro-inflammatory cytokines, such as interleukin (IL)-6,
IL-1b, and tumor necrosis factor (TNF)-a. These cyto-
kines initiate a local and systemic inflammatory
response, which includes the hepatic synthesis and
release of acute phase proteins, such as C-reactive pro-
tein (CRP) and fibrinogen [11]. Peripheral pro-inflam-
matory cytokines also signal the brain, resulting in
symptoms of sickness that typically accompany infec-
tious disease, such as fever, depressed affect, suppressed
appetite, increased sleep, and cognitive deficits [12,13].
Circulating levels of pro-inflammatory mediators are
widely accepted as a marker of systemic levels of inflam-
mation. However, caution should be taken in assuming
these inflammatory mediators are immune-derived as
many cells produce these signaling proteins, including
adipocytes and endothelial cells [14]. Regardless of
source, circulating levels of IL-6 are relatively stable
over extended periods [15], are positively related to age
[16], and predict risk for a range of age-associated dis-
eases [17]. Consistent evidence also shows that indivi-
duals with major depressive disorder have higher levels
of circulating markers of inflammation than non-
depressed individuals. For example, two recent meta-
analyses concluded that increased plasma levels of TNF-
a, IL-6, IL-1, and CRP accompany major depression
[18,19].
Available data suggest that relationships between pro-
inflammatory cytokines and depressed mood are bi-
directional. In support of immune-to-brain pathways,
sickness symptoms mediated by increases in circulating
pro-inflammatory cytokines are consistent with symp-
toms of depression including fatigue, sleep disturbances,
anxiety, negative mood, anhedonia, and loss of appetite
[20]. Indeed, the experimental or clinical administration
of cytokines or endotoxins results in a range of symp-
toms of depression [21]. For example, clinical adminis-
tration of the pro-inflammatory cytokine interferon
(IFN)-a in the treatment of cancer or chronic infection
induces symptoms of major depressive disorder in 23%
to 45% of all patients, with the degree of depression
being positively related to dose and duration of treat-
ment [22]. Epidemiologic evidence also shows that sys-
temic inflammation predicts future risk for depressive
symptoms and clinical episodes of depression in some
[23-25], but not all longitudinal studies [26,27].
To examine the impact of peripheral inflammation on
the central nervous system, recent attention has focused
on whether immune-related patterns of brain activation
are consistent with those that accompany clinical
depression. Here, animal studies show that pro-inflam-
matory cytokines can penetrate the blood-brain barrier
to stimulate the production of central pro-inflammatory
cytokines by microglial cells in discrete brain regions
that are involved in mood regulation and reward proces-
sing [20]. Recent human studies have employed rando-
mized double-blind trials, exposing subjects to either
immune stimulants (usually endotoxin) that generate
low-grade systemic inflammatory responses or saline
placebo and then comparing patterns of brain activation
across the groups using functional magnetic resonance
imagery. Using these methods, peripheral inflammation
has been associated with negative mood states that are
accompanied by increased activation of the subgenual
anterior cingulate cortex (sgACC) and decreased con-
nectivity of the sgACC with the amygdala, prefrontal
cortex, nucleus accumbens, and superior temporal sul-
cus in response to emotional stimuli [28]. A similar pat-
tern of heightened sgACC activity has been observed in
response to IFN-a treatment [29] and during episodes
of major depression, with activity returning to normative
levels once symptoms remit [30]. Peripheral administra-
tion of endotoxin also reduces activity in the ventral
striatum in response to a monetary reward task, a region
of the brain implicated in the pleasurable effects of
reward [31]. Taken together, these results raise the pos-
sibility that inflammation plays a role in the pathophy-
siology of the affective and anhedonic symptoms of
depression [32].
In addition to immune-to-brain pathways, evidence
also shows that negative mood states, stressful experi-
ences, and antagonistic dispositions can activate periph-
eral physiologic pathways that modulate immune
function. For example, negative moods are associated
with activation of the hypothalamic-pituitary-adrenal
(HPA) axis and the peripheral release of cortisol, along
with increased activation of the sympathetic and
decreased activation of the parasympathetic branches of
the autonomic nervous system [33,34]. These physiolo-
gic responses modulate the activity of immune cells and
are associated with increased production of pro-inflam-
matory cytokines [35] and levels of systemic inflamma-
tion [36]. Indeed, symptoms of depression have been
positively associated with production of TNF-a by
monocytes of healthy men and women [37,38]. Further-
more, some longitudinal studies show that symptoms of
depression precede increases in systemic inflammation
rather than result from them [26,39,27].
Conclusion
In sum, converging evidence supports reciprocal path-
ways linking inflammation and the disruption of mood.
It is likely that these pathways are part of a complex
feedback loop that involves the neuroendocrine and
Messay et al. Biology of Mood & Anxiety Disorders 2012, 2:4
http://www.biolmoodanxietydisord.com/content/2/1/4
Page 2 of 4
immune systems and plays a role in both the modula-
tion of peripheral inflammatory responses to stimuli and
the maintenance of homeostatic balance. Further
research examining specific symptoms and the central
processes involved in these circuits is warranted to fully
understand the role of inflammation in the pathophy-
siology of depression and of associated health morbidity.
Evidence suggests that examining the impact of periph-
eral inflammation on central processes that play a role
in specific symptoms of depression may point to novel
targets for future intervention. For instance, Motivala et
al. [40] found that changes in sleep during depression
shared a stronger association with peripheral pro-
inflammatory cytokines than other symptoms. Further
research is also warranted to examine whether age-
related increases in systemic inflammation impact brain
function and thus contribute to late-life depression.
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